Jodi T Williams

This inventor holds 17 USPTO granted patents and 6 published patent applications, plus 7 CIPO patents and 11 EPO patents, primarily in Orexin Receptor Antagonists. Top assignees: Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jodi T Williams. Retrieved from https://idiyas.com/inventor/jodi-t-williams

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 6)

% Patents Active = 70.6

CIPO Patents = 7 (Patent Applications = 6)

EPO Patents = 11 (Patent Applications = 18)

Average Co-Inventor Count = 6.4

ph-index = 4

Forward Citations = 53(Granted Patents)

Location History:

Basel, CH (2012 - 2016)
Allschwil, CH (2015 - 2021)

Company Filing History:

9 out of 217

Actelion Pharmaceuticals Ltd

patents

8 out of 81

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

Orexin Receptor Antagonists

Benzimidazole-Proline Derivatives

Azetidine Amide Derivatives

Pyrazole Derivatives

Imidazole Derivatives

Proline Sulfonamide Derivatives

Lactam Derivatives

Crystalline Salt Forms

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12344597 - Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis (2025-07-01),

2. 11040966 - Benzimidazole-proline derivatives (2021-06-22),

3. 10329287 - Benzimidazole-proline derivatives (2019-06-25),

4. 10023560 - Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist (2018-07-17),

5. 9914721 - Use of benzimidazole-proline derivatives (2018-03-13),

6. 9914720 - Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists (2018-03-13),

7. 9790208 - Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist (2017-10-17),

8. 9732075 - Benzimidazole-proline derivatives (2017-08-15),

9. 9493446 - [object Object] (2016-11-15),

10. 9403813 - Azetidine amide derivatives as orexin receptor antagonists (2016-08-02),

11. 9303023 - Pyrazole and imidazole derivatives useful as orexin antagonists (2016-04-05),

12. 9242970 - Lactam derivatives useful as orexin receptor antagonists (2016-01-26),

13. 9211279 - Proline sulfonamide derivatives as orexin receptor antagonists (2015-12-15),

14. 9150566 - 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists (2015-10-06),

15. 9000029 - Proline sulfonamide derivatives as orexin receptor antagonists (2015-04-07),

Title: The Innovative Journey of Jodi T Williams

Introduction: Jodi T Williams, a pioneering inventor based in Basel, Switzerland, has made significant contributions to the field of technology and innovation.

Latest Patents: Jodi T Williams holds several patents in the areas of biotechnology, pharmaceuticals, and medical devices, showcasing his diverse range of expertise and creativity.

Career Highlights: With a career spanning over two decades, Jodi T Williams has worked with renowned research institutions and leading companies to develop groundbreaking solutions that have had a profound impact on various industries.

Collaborations: Throughout his career, Jodi T Williams has collaborated with top scientists, engineers, and researchers from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Jodi T Williams continues to inspire the next generation of inventors with his passion for pushing the boundaries of what is possible, leaving a lasting legacy in the world of technology and innovation.

Profile summary based on public USPTO records.